This page shows the latest lymphoma news and features for those working in and with pharma, biotech and healthcare.
In final draft guidance, NICE recommended the antibody drug conjugate be used in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) for untreated diffuse large B-cell lymphoma (DLBCL).
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma. ... Specifically, the therapy is now
BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), the company announced. ... lymphoma (MZL) who have received
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody currently under development for the treatment of B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle ... it the first and only
and prednisone (R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL). ... This was evaluated by the investigator using the Lugano Response Criteria for malignant lymphoma.
Ryan Jacobs, principal study investigator, clinical director, division of lymphoma therapy and research, department of haematologic oncology, Atrium Health Levine Cancer Institute.
More from news
Approximately 75 fully matching, plus 412 partially matching documents found.
In mantle cell lymphoma – where patients often require unpleasant stem cell transplantation procedures – TKI growth-blocker technology is increasing failure-free survival rates in younger patients.
Special interest sessions during the ASH-FDA Joint Symposium picked out advances in disease states as diverse as multiple myeloma, B-cell lymphoma and AML, while in non-malignant haematology it ... One of the most groundbreaking announcements came in
large B-cell lymphoma, acute lymphoblastic leukaemia and other relapsed/ refractory haematologic cancer. ... tumour antigens, such as CD-19, CD20 and CD22, found predominantly in leukaemia and lymphoma.
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
CAR-T therapy has potential across all tumour types, with recent results showing impressive overall response rates and complete response rates in patients with aggressive B-cell lymphomas.
More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.
Previously, he spent many years at Celgene, where he was corporate vice president for clinical R7D and the therapeutic area head for Lymphoma and CLL.
Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
We’ve done this for 8 conferences this year, events like the Neurology Exchange, The Annual T-Cell Lymphoma Forum, Psychiatry Winter Update and we will be doing even more in
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide.
refractory diffuse large B-cell lymphoma.
s Lymphoma and Parkinsons.
such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two sessions.
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...